Testing two cancer drugs together for ovarian cancer

Plain-English translation of NCT06976892 on ClinicalTrials.gov ↗ · Source last updated August 2025 · Translation generated June 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This trial is testing a combination of two medications: Idetrexed and olaparib. Idetrexed is designed to target cancer cells that have a specific protein on their surface, and olaparib prevents cancer cells from repairing damage to their DNA. By combining these two medications, researchers hope to kill more cancer cells than either medication could alone.

Current treatments for advanced ovarian cancer don't work for everyone, and some patients develop resistance to standard therapies. This trial is exploring whether combining these two medications in a new way could offer hope to patients who have exhausted other treatment options.

Do you qualify?

You likely qualify if…

you have been diagnosed with high-grade serous ovarian cancer that either hasn't responded to standard treatment or for which standard treatment is not an option
you have measurable cancer that can be seen on imaging or detected through tumor markers in your blood
you are 18 years or older and expected to live at least 12 weeks
you are in good enough overall health (WHO performance status 0–1) to tolerate the trial medications
your blood counts, heart function, and lung function are within safe ranges as determined by blood tests and scans

You likely don't qualify if…

you have received chemotherapy, radiation, immunotherapy, or other cancer treatments within the past 4–6 weeks
you are still experiencing serious side effects from previous cancer treatments
you have untreated cancer that has spread to your brain, or new brain metastases
you are pregnant, breastfeeding, or planning to become pregnant during or within 6 months after the trial
you have active, uncontrolled infection or certain chronic diseases, or have tested positive for hepatitis B, hepatitis C, or HIV

What participation looks like

You will receive Idetrexed as an intravenous infusion twice per month (on days 1 and 15 of each treatment cycle) and take olaparib pills by mouth on specific days of each cycle. The exact doses may vary as the trial determines the safest and most effective combination. You will have regular blood tests, heart monitoring, and scans to check how you're responding and watch for side effects. The trial is still enrolling patients, so the exact length of participation will depend on how well you respond to treatment.

AI-generated summary from trial data · Jun 12, 2026 · Not medical advice

Testing two cancer drugs together for ovarian cancer

What is this trial?

Do you qualify?

What participation looks like

Trial locations